Moreover, pharmacological targeting of PRMT3 can inhibit GBM cell growth by suppressing HIF1A expression and glycolysis, revealing PRMT3's key role in GBM growth and progression and suggesting it as a potential target for GBM therapy. The gene discussed is HIF1A; the disease is glioblastoma.